Risk of cervical cancer associated with extending the interval between cervical-cancer screenings

被引:92
作者
Sawaya, GF [1 ]
McConnell, KJ
Kulasingam, SL
Lawson, HW
Kerlikowske, K
Melnikow, J
Lee, NC
Gildengorin, G
Myers, ER
Washington, AE
机构
[1] Dept Vet Affairs, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94121 USA
[2] Dept Vet Affairs, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA
[3] Dept Vet Affairs, Dept Med, San Francisco, CA 94121 USA
[4] Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94121 USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Oregon Hlth Sci Univ, Dept Emergency Med Publ Hlth & Prevent Med, Portland, OR 97201 USA
[7] Duke Univ, Dept Obstet & Gynecol, Durham, NC 27710 USA
[8] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA
[9] Univ Calif Davis, Dept Family & Community Med, Sacramento, CA 95817 USA
关键词
D O I
10.1056/NEJMoa035419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Although contemporary guidelines suggest that the intervals between Papanicolaou tests can be extended to three years among low-risk women with previous negative tests, the excess risk of cervical cancer associated with less frequent than annual screening is uncertain. METHODS: We determined the prevalence of biopsy-proven cervical neoplasia among 938,576 women younger than 65 years of age, stratified according to the number of previous consecutive negative Papanicolaou tests. Using a Markov model that estimates the rate at which dysplasia will progress to cancer, we estimated the risk of cancer within three years after one or more negative Papanicolaou tests, as well as the number of additional Papanicolaou tests and colposcopic examinations that would be required to avert one case of cancer given a particular interval between screenings. RESULTS: Among 31,728 women 30 to 64 years of age who had had three or more consecutive negative tests, the prevalence of biopsy-proven cervical intraepithelial neoplasia of grade 2 was 0.028 percent and the prevalence of grade 3 neoplasia was 0.019 percent; none of the women had invasive cervical cancer. According to our model, the estimated risk of cancer with annual Papanicolaou tests for three years was 2 in 100,000 among women 30 to 44 years of age, 1 in 100,000 among women 45 to 59 years of age, and 1 in 100,000 among women 60 to 64 years of age; these risks would be 5 in 100,000, 2 in 100,000, and 1 in 100,000, respectively, if screening were performed once three years after the last negative test. To avert one additional case of cancer by screening 100,000 women annually for three years rather than once three years after the last negative test, an average of 69,665 additional Papanicolaou tests and 3861 colposcopic examinations would be needed in women 30 to 44 years of age and an average of 209,324 additional Papanicolaou tests and 11,502 colposcopic examinations in women 45 to 59 years of age. CONCLUSIONS: As compared with annual screening for three years, screening performed once three years after the last negative test in women 30 to 64 years of age who have had three or more consecutive negative Papanicolaou tests is associated with an average excess risk of cervical cancer of approximately 3 in 100,000.
引用
收藏
页码:1501 / 1509
页数:9
相关论文
共 49 条
[1]  
Agency for Health Care Policy and Research, 1999, AHCPR PUBL, V99-0034
[2]  
BEARMAN DM, 1987, OBSTET GYNECOL, V69, P660
[3]   Shanxi province cervical cancer screening study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia (vol 83, pg 439, 2001) [J].
Belinson, J ;
Qiao, YL ;
Pretorius, R ;
Zhang, WH ;
Elson, P ;
Li, L ;
Pan, QJ ;
Fischer, C ;
Lorincz, A ;
Zahniser, D .
GYNECOLOGIC ONCOLOGY, 2002, 84 (02) :355-355
[4]  
CHAN PG, IN PRESS OBSTET GYNE
[5]   HUMAN PAPILLOMAVIRUS TESTING IN PRIMARY CERVICAL SCREENING [J].
CUZICK, J ;
SZAREWSKI, A ;
TERRY, G ;
HO, L ;
HANBY, A ;
MADDOX, P ;
ANDERSON, M ;
KOCJAN, G ;
STEELE, ST ;
GUILLEBAUD, J .
LANCET, 1995, 345 (8964) :1533-1536
[6]  
DEVESA SS, 1989, CANCER, V64, P2184, DOI 10.1002/1097-0142(19891115)64:10<2184::AID-CNCR2820641034>3.0.CO
[7]  
2-8
[8]  
Duggan MA, 1998, EUR J GYNAECOL ONCOL, V19, P338
[9]   SCREENING FOR CERVICAL-CANCER [J].
EDDY, DM .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (03) :214-226
[10]   COST-EFFECTIVENESS OF CERVICAL-CANCER SCREENING FOR THE ELDERLY [J].
FAHS, MC ;
MANDELBLATT, J ;
SCHECHTER, C ;
MULLER, C .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (06) :520-527